MX2023009135A - Compuestos de oxazepina tetraciclica y usos de estos. - Google Patents
Compuestos de oxazepina tetraciclica y usos de estos.Info
- Publication number
- MX2023009135A MX2023009135A MX2023009135A MX2023009135A MX2023009135A MX 2023009135 A MX2023009135 A MX 2023009135A MX 2023009135 A MX2023009135 A MX 2023009135A MX 2023009135 A MX2023009135 A MX 2023009135A MX 2023009135 A MX2023009135 A MX 2023009135A
- Authority
- MX
- Mexico
- Prior art keywords
- tetracyclic
- oxazepine compounds
- compounds
- oxazepine
- oxazepinyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/16—Peri-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2021076369 | 2021-02-09 | ||
| CN2022074435 | 2022-01-27 | ||
| PCT/US2022/015407 WO2022173678A1 (en) | 2021-02-09 | 2022-02-07 | Tetracyclic oxazepine compounds and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023009135A true MX2023009135A (es) | 2023-08-16 |
Family
ID=80445964
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023009135A MX2023009135A (es) | 2021-02-09 | 2022-02-07 | Compuestos de oxazepina tetraciclica y usos de estos. |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20220281893A1 (enExample) |
| EP (1) | EP4291563A1 (enExample) |
| JP (1) | JP7862413B2 (enExample) |
| KR (1) | KR20230145078A (enExample) |
| CN (1) | CN116867792A (enExample) |
| AU (1) | AU2022218927A1 (enExample) |
| CA (1) | CA3210167A1 (enExample) |
| IL (1) | IL304700A (enExample) |
| MX (1) | MX2023009135A (enExample) |
| TW (1) | TWI824405B (enExample) |
| WO (1) | WO2022173678A1 (enExample) |
Families Citing this family (70)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112020020307A2 (pt) | 2018-04-04 | 2021-01-12 | Arvinas Operations, Inc. | Moduladores de proteólise e métodos de uso associados |
| CN117043167A (zh) * | 2021-03-17 | 2023-11-10 | 劲方医药科技(上海)有限公司 | 嘧啶并环类化合物及其制法和用途 |
| MX2023015533A (es) * | 2021-06-21 | 2024-01-23 | Jiangsu Hengrui Pharmaceuticals Co Ltd | Compuesto tetraciclico fusionado, metodo de preparacion y aplicacion en medicina. |
| CN115557974A (zh) * | 2021-07-02 | 2023-01-03 | 上海迪诺医药科技有限公司 | Kras g12d抑制剂及其应用 |
| TW202315626A (zh) * | 2021-08-31 | 2023-04-16 | 大陸商勁方醫藥科技(上海)有限公司 | 嘧啶并環類化合物及其製法和用途 |
| CN118019746A (zh) * | 2021-09-27 | 2024-05-10 | 北京加科思新药研发有限公司 | 多环稠环衍生物及其用途 |
| WO2023103906A1 (zh) * | 2021-12-07 | 2023-06-15 | 贝达药业股份有限公司 | Kras g12d抑制剂及其在医药上的应用 |
| JP2025504041A (ja) * | 2022-01-30 | 2025-02-06 | シャンハイ ファーマシューティカルズ ホールディング カンパニー，リミティド | キノリン系化合物及びその使用 |
| EP4491673A4 (en) * | 2022-03-08 | 2026-03-18 | Shinetsu Chemical Co | TWO-COMPONENT ADDITION-CURDED THERMOCONDUCTIVE SILICONE COMPOSITION, AND A HARDENED SILICONE OBJECT THEREIN |
| WO2023172940A1 (en) | 2022-03-08 | 2023-09-14 | Revolution Medicines, Inc. | Methods for treating immune refractory lung cancer |
| CN119365467A (zh) | 2022-05-19 | 2025-01-24 | 基因泰克公司 | 氮杂-四环氧氮杂䓬化合物及其用途 |
| EP4536364A1 (en) | 2022-06-10 | 2025-04-16 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| WO2024008178A1 (zh) * | 2022-07-08 | 2024-01-11 | 贝达药业股份有限公司 | Kras g12d抑制剂及其在医药上的应用 |
| CN117430620A (zh) * | 2022-07-22 | 2024-01-23 | 上海医药集团股份有限公司 | 嘧啶环类化合物、其中间体、其药物组合物及其应用 |
| TW202409051A (zh) | 2022-07-27 | 2024-03-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 稠環類化合物、其製備方法及其在醫藥上的應用 |
| AU2023320565A1 (en) | 2022-08-05 | 2025-01-23 | Kumquat Biosciences Inc. | Heterocyclic compounds and uses thereof |
| WO2024041621A1 (en) * | 2022-08-25 | 2024-02-29 | Jacobio Pharmaceuticals Co., Ltd. | K-ras mutant protein inhibitors |
| WO2024041573A1 (en) * | 2022-08-25 | 2024-02-29 | Zai Lab (Shanghai) Co., Ltd. | Fused multi-heterocyclic compounds as kras g12d modulators and uses thereof |
| WO2024051721A1 (en) * | 2022-09-07 | 2024-03-14 | Nikang Therapeutics, Inc. | Tetracyclic derivatives as kras inhibitors |
| WO2024138486A1 (en) * | 2022-12-29 | 2024-07-04 | Nikang Therapeutics, Inc. | Tetracyclic derivatives as kras inhibitors |
| TW202426459A (zh) * | 2022-09-23 | 2024-07-01 | 大陸商勁方醫藥科技(上海)有限公司 | 嘧啶并環類化合物及其製法和用途 |
| JP2025532125A (ja) * | 2022-09-23 | 2025-09-29 | アイディーエンス カンパニー リミテッド | 新規なテトラヘテロサイクル化合物 |
| TW202440594A (zh) * | 2022-12-07 | 2024-10-16 | 大陸商北京加科思新藥研發有限公司 | 稠環化合物及其用途 |
| JP2025541435A (ja) * | 2022-12-23 | 2025-12-18 | 上海和誉生物医薬科技有限公司 | Ｋｒａｓ ｇ１２ｄ阻害剤及びその応用 |
| WO2024149214A1 (en) * | 2023-01-10 | 2024-07-18 | Nikang Therapeutics, Inc. | Bifunctional compounds for degrading kras-12d via ubiquitin proteasome pathway |
| CN122187841A (zh) * | 2023-01-18 | 2026-06-12 | 苏州赞荣医药科技有限公司 | Kras g12d抑制剂和其用途 |
| CN120548318A (zh) * | 2023-01-18 | 2025-08-26 | 苏州赞荣医药科技有限公司 | Kras g12d抑制剂和其用途 |
| CN120500487A (zh) * | 2023-01-18 | 2025-08-15 | 上海艾力斯医药科技股份有限公司 | 杂环类化合物、其药物组合物及其用途 |
| PE20260006A1 (es) | 2023-01-26 | 2026-01-06 | Arvinas Operations Inc | Protacs degradadores de kras basados en cereblon y usos relacionados con los mismos |
| WO2024178304A1 (en) * | 2023-02-24 | 2024-08-29 | Alterome Therapeutics, Inc. | Kras modulators |
| CN121487738A (zh) | 2023-03-30 | 2026-02-06 | 锐新医药公司 | 诱导ras gtp水解的组合物和其用途 |
| WO2024211712A1 (en) | 2023-04-07 | 2024-10-10 | Revolution Medicines, Inc. | Condensed macrocyclic compounds as ras inhibitors |
| CN121487951A (zh) | 2023-04-07 | 2026-02-06 | 锐新医药公司 | 大环ras抑制剂 |
| EP4695261A1 (en) | 2023-04-14 | 2026-02-18 | Revolution Medicines, Inc. | Crystalline forms of ras inhibitors, compositions containing the same, and methods of use thereof |
| AU2024251341A1 (en) | 2023-04-14 | 2025-10-16 | Revolution Medicines, Inc. | Crystalline forms of a ras inhibitor |
| KR20260019479A (ko) | 2023-05-04 | 2026-02-10 | 레볼루션 메디슨즈, 인크. | Ras 관련 질환 또는 장애를 위한 병용 요법 |
| EP4716531A2 (en) * | 2023-05-22 | 2026-04-01 | Board of Regents, The University of Texas System | Heterocyclic compounds as nras inhibitors |
| CN121843945A (zh) * | 2023-07-18 | 2026-04-10 | 泰励生物科技（上海）有限公司 | 具有抗kras突变肿瘤活性的化合物 |
| CN121889155A (zh) | 2023-08-07 | 2026-04-17 | 锐新医药公司 | 用于治疗ras蛋白相关疾病或病症的rmc-6291 |
| US20250109147A1 (en) | 2023-09-08 | 2025-04-03 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| AU2024360465A1 (en) | 2023-10-12 | 2026-04-09 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| CN117430564A (zh) * | 2023-10-18 | 2024-01-23 | 爱斯特（成都）生物制药股份有限公司 | 一种7-溴-2,6-二氯-5,8-二氟噻唑啉-4(3h)-酮的制备方法 |
| TW202540122A (zh) * | 2023-11-22 | 2025-10-16 | 美商建南德克公司 | Ｋｒａｓ－ｇ１２ｄ之氮雜－四環氧氮呯抑制劑的多晶型物及合成方法 |
| CN119684315B (zh) * | 2024-01-26 | 2026-05-12 | 苏州盛迪亚生物医药有限公司 | 一种苯并噻吩取代稠环化合物的结晶形式及其制备方法 |
| CN119490512B (zh) * | 2024-01-26 | 2026-06-16 | 苏州盛迪亚生物医药有限公司 | 一种苯并噻吩取代稠环化合物的可药用盐、其结晶形式及用途 |
| WO2025157261A1 (zh) * | 2024-01-26 | 2025-07-31 | 江苏恒瑞医药股份有限公司 | G12d抑制剂化合物晶型及其制备方法 |
| CN119661555B (zh) * | 2024-01-26 | 2026-04-14 | 苏州盛迪亚生物医药有限公司 | 一种稠环类化合物的可药用盐、其结晶形式及用途 |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025209456A1 (zh) * | 2024-04-03 | 2025-10-09 | 北京泰德制药股份有限公司 | 血管紧张素ii 2型受体拮抗剂及其用于治疗癌性疼痛的用途 |
| TW202608891A (zh) * | 2024-04-19 | 2026-03-01 | 大陸商領泰生物醫藥（紹興）有限公司 | Ｋｒａｓ ｇ１２ｄ降解劑及其製備方法與應用 |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| US20250375445A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025256655A1 (zh) * | 2024-06-14 | 2025-12-18 | 上海翰森生物医药科技有限公司 | 一种含嘧啶多元并环类衍生物抑制剂的晶型及其制备方法 |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
| WO2026073024A1 (en) * | 2024-09-30 | 2026-04-02 | Gilead Sciences, Inc. | Kras g12d inhibitors for the treatment of cancer |
| WO2026090116A2 (en) | 2024-10-21 | 2026-04-30 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026090245A1 (en) | 2024-10-22 | 2026-04-30 | Revolution Medicines, Inc. | Use of ras inhibitors for treating cancer |
| US20260108528A1 (en) | 2024-10-22 | 2026-04-23 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2026106912A1 (en) | 2024-11-12 | 2026-05-21 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026112260A1 (en) | 2024-11-21 | 2026-05-28 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026122764A2 (en) | 2024-12-06 | 2026-06-11 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026128688A2 (en) | 2024-12-13 | 2026-06-18 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026161839A1 (en) | 2025-01-27 | 2026-07-30 | Revolution Medicines, Inc. | Ras inhibitors |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US5543523A (en) | 1994-11-15 | 1996-08-06 | Regents Of The University Of Minnesota | Method and intermediates for the synthesis of korupensamines |
| WO2018206539A1 (en) * | 2017-05-11 | 2018-11-15 | Astrazeneca Ab | Heteroaryl compounds that inhibit g12c mutant ras proteins |
| TW202012415A (zh) * | 2018-05-08 | 2020-04-01 | 瑞典商阿斯特捷利康公司 | 化學化合物 |
| WO2020097537A2 (en) * | 2018-11-09 | 2020-05-14 | Genentech, Inc. | Fused ring compounds |
| WO2021215544A1 (en) * | 2020-04-24 | 2021-10-28 | Taiho Pharmaceutical Co., Ltd. | Kras g12d protein inhibitors |
| US20240199644A1 (en) * | 2021-03-07 | 2024-06-20 | Jacobio Pharmaceuticals Co., Ltd. | Fused Ring Derivatives Useful as KRAS G12D Inhibitors |
| CN117043167A (zh) * | 2021-03-17 | 2023-11-10 | 劲方医药科技(上海)有限公司 | 嘧啶并环类化合物及其制法和用途 |
| CN117083281A (zh) * | 2021-03-24 | 2023-11-17 | 南京明德新药研发有限公司 | 嘧啶并杂环类化合物及其应用 |
| WO2022206723A1 (zh) * | 2021-03-30 | 2022-10-06 | 浙江海正药业股份有限公司 | 杂环类衍生物、其制备方法及其医药上的用途 |
| MX2023015533A (es) * | 2021-06-21 | 2024-01-23 | Jiangsu Hengrui Pharmaceuticals Co Ltd | Compuesto tetraciclico fusionado, metodo de preparacion y aplicacion en medicina. |
| CA3226720A1 (en) * | 2021-07-23 | 2023-01-26 | Suzhou Zanrong Pharma Limited | Kras g12d inhibitors and uses thereof |
| TW202315626A (zh) * | 2021-08-31 | 2023-04-16 | 大陸商勁方醫藥科技(上海)有限公司 | 嘧啶并環類化合物及其製法和用途 |
-
2022
- 2022-02-07 CN CN202280014071.XA patent/CN116867792A/zh active Pending
- 2022-02-07 EP EP22705680.1A patent/EP4291563A1/en active Pending
- 2022-02-07 US US17/666,350 patent/US20220281893A1/en not_active Abandoned
- 2022-02-07 TW TW111104429A patent/TWI824405B/zh active
- 2022-02-07 WO PCT/US2022/015407 patent/WO2022173678A1/en not_active Ceased
- 2022-02-07 MX MX2023009135A patent/MX2023009135A/es unknown
- 2022-02-07 KR KR1020237027846A patent/KR20230145078A/ko active Pending
- 2022-02-07 CA CA3210167A patent/CA3210167A1/en active Pending
- 2022-02-07 AU AU2022218927A patent/AU2022218927A1/en active Pending
- 2022-02-07 JP JP2023547523A patent/JP7862413B2/ja active Active
-
2023
- 2023-07-24 IL IL304700A patent/IL304700A/en unknown
-
2024
- 2024-09-11 US US18/882,588 patent/US20250042919A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2022218927A1 (en) | 2023-08-03 |
| US20250042919A1 (en) | 2025-02-06 |
| IL304700A (en) | 2023-09-01 |
| TW202241912A (zh) | 2022-11-01 |
| TWI824405B (zh) | 2023-12-01 |
| JP7862413B2 (ja) | 2026-05-19 |
| AU2022218927A9 (en) | 2024-09-19 |
| WO2022173678A1 (en) | 2022-08-18 |
| CA3210167A1 (en) | 2022-08-18 |
| US20220281893A1 (en) | 2022-09-08 |
| KR20230145078A (ko) | 2023-10-17 |
| JP2024506029A (ja) | 2024-02-08 |
| CN116867792A (zh) | 2023-10-10 |
| EP4291563A1 (en) | 2023-12-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202408076B (en) | Aza-tetracyclic oxazepine compounds and uses thereof | |
| AR058505A1 (es) | Combinaciones antineoplasicas de temsirolimus y malato de sunitinib | |
| AU307833S (en) | Can insulator | |
| AU303136S (en) | Bottle | |
| AU303134S (en) | Bottle | |
| AU301549S (en) | Bottle | |
| AU302959S (en) | Toothbrush | |
| MX2018002723A (es) | Macrociclicos peptidomimeticos y usos de los mismos. | |
| AU301340S (en) | Manual sharpener | |
| PH12022553333A1 (en) | Markers for use in methods for treating cancers with antibody drug conjugates (adc) | |
| AU304504S (en) | Lancet device | |
| UA83022C2 (uk) | Аплідин для комбінованої терапії лейкозу та лімфоми | |
| FR2945210B1 (fr) | Combinaison antitumorale comprenant l'ave8062 et le sorafenib | |
| MX2024013869A (es) | Conjugados anticuerpo-farmaco 5t4 y usos de los mismos | |
| TW200641091A (en) | Organometallic complexes | |
| AU303295S (en) | Belt | |
| AU309683S (en) | Massaging belt | |
| AU302025S (en) | Karaoke microphone | |
| AU300156S (en) | Underwear | |
| AU300467S (en) | Bottle | |
| CA115177S (en) | Blood or plasma treatment apparatus | |
| AU305866S (en) | Refrigeration machinery and apparatus | |
| AU304496S (en) | Bottle and doser | |
| AU300329S (en) | Tablet | |
| AU301495S (en) | Sander |